tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 Nov;19(11):e70193.
doi: 10.1111/irv.70193. Relative Effectiveness of High-Dose vs. Standard-Dose Influenza Vaccines in Preventing Hospitalizations: A National Retrospective Cohort Study in France, 2022/2023 Season
Hélène Bricout[SUP] 1 [/SUP], Marie-Cécile Levant[SUP] 1 [/SUP], Pascal Crépey[SUP] 2 [/SUP], Gaëtan Gavazzi[SUP] 3 4 [/SUP], Jacques Gaillat[SUP] 5 [/SUP], Marine Dufournet[SUP] 6 [/SUP], Nada Assi[SUP] 7 [/SUP], Benjamin Grenier[SUP] 8 [/SUP], Fanny Raguideau[SUP] 8 [/SUP], Fabienne Péretz[SUP] 9 [/SUP], Camille Salamand[SUP] 6 [/SUP], Anne Mosnier[SUP] 10 [/SUP], Laurence Watier[SUP] 11 [/SUP], Odile Launay[SUP] 12 [/SUP], Matthew M Loiacono[SUP] 13 [/SUP]
Affiliations
Background: A French cohort study (2021/2022 influenza season) found the high-dose influenza vaccine (HD) more effective than standard-dose vaccines (SDs) in preventing influenza-related hospitalizations in the elderly. The study continued to refine results and validate these findings.
Methods: Data from community-dwelling 65+ adults who received HD or SD during the 2022/2023 vaccination campaign were extracted from the National Health database. Hospitalizations were recorded from 14 days postvaccination until June 30, 2023. HD and SD recipients were matched using a propensity score. Associations between vaccines and hospitalizations were assessed by estimating incidence rate ratios and converting them to HD vs. SD vaccine relative effectiveness (rVE).
Results: A total of 675,412 HD recipients were matched to 2,701,648 SD recipients. The rVE for influenza-related hospitalizations was 27.4% [95% CI: 19.8; 34.3]. It ranged from 22.7% [9.8; 33.6] to 33.6% [21.2; 44.0] across age groups, indicating that HD consistently outperformed SDs in preventing influenza-related hospitalizations, with the highest effect observed in 85+.
Conclusions: Our study is the first to publish rVE data comparing HD and SDs in a real-world setting in France for the 2022/2023 influenza season. Its findings reaffirm the benefit of HD vs. SDs. HD could help reduce the burden of severe respiratory infections in the elderly.
Keywords: France; aged; factual databases; hospitalization; influenza vaccines; medical informatics; vaccine effectiveness.
. 2025 Nov;19(11):e70193.
doi: 10.1111/irv.70193. Relative Effectiveness of High-Dose vs. Standard-Dose Influenza Vaccines in Preventing Hospitalizations: A National Retrospective Cohort Study in France, 2022/2023 Season
Hélène Bricout[SUP] 1 [/SUP], Marie-Cécile Levant[SUP] 1 [/SUP], Pascal Crépey[SUP] 2 [/SUP], Gaëtan Gavazzi[SUP] 3 4 [/SUP], Jacques Gaillat[SUP] 5 [/SUP], Marine Dufournet[SUP] 6 [/SUP], Nada Assi[SUP] 7 [/SUP], Benjamin Grenier[SUP] 8 [/SUP], Fanny Raguideau[SUP] 8 [/SUP], Fabienne Péretz[SUP] 9 [/SUP], Camille Salamand[SUP] 6 [/SUP], Anne Mosnier[SUP] 10 [/SUP], Laurence Watier[SUP] 11 [/SUP], Odile Launay[SUP] 12 [/SUP], Matthew M Loiacono[SUP] 13 [/SUP]
Affiliations
- PMID: 41243190
- DOI: 10.1111/irv.70193
Background: A French cohort study (2021/2022 influenza season) found the high-dose influenza vaccine (HD) more effective than standard-dose vaccines (SDs) in preventing influenza-related hospitalizations in the elderly. The study continued to refine results and validate these findings.
Methods: Data from community-dwelling 65+ adults who received HD or SD during the 2022/2023 vaccination campaign were extracted from the National Health database. Hospitalizations were recorded from 14 days postvaccination until June 30, 2023. HD and SD recipients were matched using a propensity score. Associations between vaccines and hospitalizations were assessed by estimating incidence rate ratios and converting them to HD vs. SD vaccine relative effectiveness (rVE).
Results: A total of 675,412 HD recipients were matched to 2,701,648 SD recipients. The rVE for influenza-related hospitalizations was 27.4% [95% CI: 19.8; 34.3]. It ranged from 22.7% [9.8; 33.6] to 33.6% [21.2; 44.0] across age groups, indicating that HD consistently outperformed SDs in preventing influenza-related hospitalizations, with the highest effect observed in 85+.
Conclusions: Our study is the first to publish rVE data comparing HD and SDs in a real-world setting in France for the 2022/2023 influenza season. Its findings reaffirm the benefit of HD vs. SDs. HD could help reduce the burden of severe respiratory infections in the elderly.
Keywords: France; aged; factual databases; hospitalization; influenza vaccines; medical informatics; vaccine effectiveness.